Talphera Inc (TLPH) Diversifiers

Equity · Currency in USD · Last updated Jun 4, 2026

Talphera, Inc. focuses on the development and commercialization of therapies for use in medically supervised settings, with lead product candidates including Niyad, a lyophilized formulation of nafamostat as an anticoagulant for extracorporeal circuits, and LTX-608, a nafamostat formulation for direct IV infusion targeting various indications such as antiviral and acute respiratory distress syndrome. The company is also developing Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates.

Looking to balance out your exposure to TLPH? The ETFs below have the lowest correlation with TLPH — they tend to move on their own, which can help reduce risk when TLPH drops. The stock ideas table highlights individual companies that behave independently from TLPH.

No Diversifiers Found for TLPH

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements TLPH

Add TLPH to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with TLPH